Sanna-maria Kakonen

Turku, 20520, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models.

Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models.

Journal: International journal of molecular sciences

Published: November 13, 2024

Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model.

Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model.

Journal: Cancers

Published: July 06, 2023

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model.

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model.

Journal: International journal of molecular sciences

Published: November 09, 2022

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model.

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model.

Journal: International journal of molecular sciences

Published: March 31, 2021

The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis.

The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis.

Journal: International journal of molecular sciences

Published: July 28, 2019

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 28, 2016

Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.

Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.

Journal: Journal of the National Cancer Institute

Published: May 18, 2013

Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis.

Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis.

Journal: Molecular cancer research : MCR

Published: April 24, 2012

Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells.

Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells.

Journal: PloS one

Published: November 23, 2011

Showing 1-9 of 9

Last Updated: 09/26/2026